Navigation Links
Hypertension & cholesterol medications present in water released into the St. Lawrence River
Date:1/26/2009

This press release is available in French.

Montreal, January 26, 2009 A study conducted by Universit de Montral researchers on downstream and upstream water from the Montreal wastewater treatment plant has revealed the presence of chemotherapy products and certain hypertension and cholesterol medications.

Bezafibrate (cholesterol reducing medication), enalapril (hypertension medication), methotrexate and cyclophosphamide (two products used in the treatment of certain cancers) have all been detected in wastewater entering the Montreal treatment station. However, only bezafibrate and enalapril have been detected in the treated water leaving the wastewater treatment plant and in the surface water of the St. Lawrence River, where the treated wastewater is released.

This study was conducted due to the sharp rise in drug consumption over the past few years. In 1999, according to a study by IMS Health Global Services, world drug consumption amounted to $342 billion. In 2006 that figure doubled to $643 billion. A significant proportion of the drugs consumed are excreted by the human body in urine and end up in municipal wastewater. Chemotherapy products, such as methotrexate, are excreted by the body practically unchanged (80 to 90 percent in their initial form).

Chemotherapy for fish?

The pharmaceutical compounds studied were chosen because of the large quantities prescribed by physicians. "Methotrexate and cyclophosphamide are two products very often used to treat cancer and are more likely to be found in water," says Sbastien Sauv, a professor of environmental chemistry at the Universit de Montral. "Even though they treat cancer, these two products are highly toxic. This is why we wanted to know the extent to which the fauna and flora of the St. Lawrence are exposed to them."

Method and quantities

Professor Sauv's team validated a rapid detection method (On-line SPE-LC-MS/MS ) (1) for pharmaceutical compounds under study in the raw and treated wastewater of the Montreal wastewater treatment plant.

The quantities of bezafibrate and enalapril detected in the raw wastewater, treated wastewater and surface water at the treatment station outlet are respectively 50 nanograms per litre, 35 ng L and 8 ng L for bezafibrate and 280 ng L, 240 ng L and 39ng L for enalapril.

"All in all, these quantities are minimal, yet we don't yet know their effects on the fauna and flora of the St. Lawrence," Professor Sauv explains. "It is possible that some species are sensitive to them. Other ecotoxicological studies will be necessary. As for the chemotherapy products detected in the raw wastewater but not in the treated wastewater, one question remains: did we not detect them because the treatment process succeeded in eliminating them or because our detection method is not yet sophisticated enough to detect them?"

A new threat to the aquatic environment

The release locations of wastewaters treated by the treatment stations are the main source of drug dispersion into the environment. Because of their high polarity and their acid-base character, some of the pharmaceutical compounds studied have the potential to be transported and dispersed widely in the aquatic environment. In Montreal, the wastewater treatment station treats a water volume representing 50 percent of the water treated in Quebec and has a capacity of about 7.6 million cubic metres per day, making it the largest physicochemical treatment station in the Americas. This is why it is important to develop a simple, rapid, precise and inexpensive method, Professor Sauv points out.


'/>"/>

Contact: Julie Gazaille
j.cordeau-gazaille@umontreal.ca
514-343-6796
University of Montreal
Source:Eurekalert

Related medicine news :

1. Study Finds Molecular Link Between Obesity, Hypertension
2. Hypertension Might Hinder Thinking
3. Daiichi Sankyo, Inc. Awarded Prestigious NCQA Certification for National Under Pressure(TM) Hypertension Management Program
4. Downgraded Tier Positions and Step Therapy Restrictions Have Stalled Exforges and Tekturnas Growth in The Hypertension Drug Market
5. Pulmonary Hypertension Treated with Stem Cells : International Medical Team Announces Patient Results in Adult Stem Cell Clinical Study for Pulmonary Hypertension
6. Hypertension May Hit Black Males Earlier
7. Lipoprotein Levels May Predict Womens Hypertension Risk
8. Poor Sleep, Hypertension a Dangerous Combination
9. Diabetes, Hypertension Hasten Death in Alzheimers Patients
10. Viagra Bulk Effectively Cures Children with PAH (Pulmonary Arterial Hypertension)
11. Women at Higher Risk for Pulmonary Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Appleton, WI (PRWEB) , ... March 28, 2017 ... ... how self-funded health plans work, the Self-Funding Success website has recently developed and ... about Self-Funded Health Plans ” was created based on common inquiries the site’s ...
(Date:3/28/2017)... CA (PRWEB) , ... March 28, 2017 , ... ... Carson Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer the recently ... balloon procedure, and this procedure adds to SkyLex Advanced Surgical’s already comprehensive ...
(Date:3/28/2017)... ... March 28, 2017 , ... Oily skin is a common and unwelcomed occurrence in people of ... a lot to offer to the discussion of dealing with excess skin oil. “Oily skin ... many home remedies that can help remove the oily shine while keeping the skin fresh ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep apnea ... with or without a referral. Sleep apnea is often left untreated because patients are ... headaches and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep ...
(Date:3/27/2017)... Philadelphia PA and London UK (PRWEB) , ... ... ... have the speed, agility and ability to gain site attention and engagement over ... DrugDev educational webinar will discuss how partnering with the ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... SAN DIEGO and VANCOUVER, British Columbia, March 27, ... SPHS ) (the "Company" or "Sophiris"), a clinical ... treatment of patients with urological diseases, today reported ... and key corporate highlights. Key ... in Clinical Development for Localized Prostate Cancer. During ...
(Date:3/27/2017)... , March 27, 2017 /PRNewswire/ - INVICTUS MD ... IVITF; FRA: 8IS) Invictus MD is pleased to announce ... shares for trading on the TSX Venture Exchange.  ... TSXV follows a year of significant achievements for Invictus-MD. ... successful test crops at AB Laboratories Inc. ("AB Labs"), ...
(Date:3/27/2017)... , March 27, 2017 The ... reach USD 16.0 billion by 2025, according to a ... prevalence of chronic diseases is anticipated to be responsible ... which thereby widens the scope for growth during the ... bariatric population, which is highly susceptible to chronic diseases, ...
Breaking Medicine Technology: